Laura Finneran

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea et al. · Cancer Discovery · 2020 · 134 citations · Full text

Medicine, Oncology, Pharmacology +13

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial

Christopher M. Nutting, Laura Finneran, Justin Roe et al. · The Lancet Oncology · 2023 · 105 citations · Full text

Medicine, Oncology, Radiation Oncology +17

The evidence-base for positive psychology interventions: a mega-analysis of meta-analyses

Alan Carr, Laura Finneran, Christine Boyd et al. · The Journal of Positive Psychology · 2023 · 80 citations

Public Health, Psychology, Meta-analysis +10

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda et al. · The Lancet Oncology · 2020 · 74 citations

Medicine, Oncology, Pharmacology +12

Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.

Christopher M. Nutting, Keith Rooney, Bernadette Foran et al. · Journal of Clinical Oncology · 2020 · 33 citations

Medicine, Otolaryngology, Radiation Oncology +17